Insights+: The US FDA New Drug Approvals in December 2019 and January 2020

The US FDA's Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 48 new products so far in 2019 However, there is a significant increase in multiple diseases while the new approvals are helping and advancing the changes to understand, diagnose and treat the diseases Our team…

BySenior EditorFebruary 21, 2020

INSIGHTS+

PharmaShots’ Most Read News of 2019

The year 2019 has been a busy year for global pharma and biotech companies involved in M&A, option & licensing agreements and gaining approvals. Our team has compiled a list of 20 most read life sciences news on PharmaShots in 2019. 1. Celltrion Signed an Exclusive Co-Marketing Agreement with Juno in Australia Juno provided sales promotion…

BySenior EditorJanuary 10, 2020

INSIGHTS+

PharmaShots’ Key Highlights of Third Quarter 2019

The third quarter of 2019 has ended with major acquisitions in the pharma and biotech industry along with multiple approvals. Starting with the latest acquisition where Biocon Biologics acquires Pfizer's Research Facility for expansion of its R&D footprints with the acceleration of the development of its biosimilars from lab to pilot scale. Previously, Amgen acquired…

BySenior EditorSeptember 7, 2019

INSIGHTS+

Insights+: Key Events of ASCO 2019

The American Society of Clinical Oncology (ASCO) is a platform for cancer experts to share views on latest advancement and new approaches in cancer research. In the 55th session of ASCO 2019, 2400+ abstracts were presented. IBM Watson Health was also a part of ASCO 2019 with its advancement in Oncology, Genomics and Patient Monitoring.…

BySenior EditorJuly 6, 2019

Insights+: The US FDA New Drug Approvals in December 2019 and January 2020

PharmaShots’ Most Read News of 2019

PharmaShots’ Key Highlights of Third Quarter 2019

Insights+: Key Events of ASCO 2019

Contact US

FOLLOW US